Chinese drugmakers are increasingly making global strides through licensing agreements with major multinational corporations, as investors pivot from traditional tech sectors, especially amid the slowdown in the AI boom. Many Chinese biotech companies are seeing significant stock gains, positioning healthcare as the leading sector in emerging markets. This trend reflects a growing interest in innovative drug development, shifting the global pharmaceutical landscape toward China, where local firms are now increasingly developing novel drugs that attract funding and partnerships from established global players. The transformation underscores China’s emerging role as a leader in pharmaceutical innovation, captivating investor attention.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.businesstimes.com.sg/companies-markets/consumer-healthcare/chinese-biotech-overtakes-ai-emerging-market-growth-trade
